Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by TP53 p.R337H Carriers.

Autor:	Sandoval RL; Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil., Polidorio N; Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil., Leite ACR; Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil., Cartaxo M; Oncology Center, Hospital Nossa Senhora das Neves, João Pessoa, Brazil., Pisani JP; Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil., Quirino CV; Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil., Cezana L; Oncology Center, Hospital Santa Rita de Cássia, Vitoria, Brazil., Pereira NG; Genetics and Genomics Department, Beneficência Portuguesa, São Paulo, Brazil., Pereira AAL; Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil., Rossi BM; Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.; Genetics and Genomics Department, Beneficência Portuguesa, São Paulo, Brazil., Achatz MI; Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 Mar 16; Vol. 12, pp. 836937. Date of Electronic Publication: 2022 Mar 16 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.836937
Abstrakt:	Breast cancer (BC) is the most prevalent malignancy in women with Li-Fraumeni syndrome (LFS). The literature on BC in LFS is limited due to its rarity worldwide. A TP53 founder pathogenic variant (c.1010G>A; p.R337H) is responsible for the higher prevalence of this syndrome among women of Brazilian ancestry. Purpose: The aim of the study was to describe the BC phenotype expressed by Brazilian female LFS carriers and compare the data between p.R337H and other TP53 germline pathogenic/likely pathogenic variants (non-p.R337H carriers). Methods: We searched for cases of TP53 germline pathogenic/likely pathogenic variant carriers affected by BC included between 2015 and 2020 in the BLiSS (Brazilian Li-Fraumeni Study) registry at the Sírio-Libanês Hospital. Results: Among 163 adult female carriers from the registry, 91 (56%) had received a BC diagnosis, including 72 p.R337H carriers. BC was the first cancer diagnosed in 90% of cases. Early onset BC (age ≤45 years) was diagnosed in 78.2% of cases (11.5% <31 years; 66.7% 31-45 years; 21.8% >45 years). The median age of BC diagnosis for p.R337H carriers was 39.5 years (range 20-69 years) compared to 34 years (range 21-63 years) for non-p.R337H carriers (p = 0.009). In total, 104 breast tumors were observed in 87 women. Bilateral BC was observed in 29.3% of cases. Histology was available for 96 tumors, comprising 69 invasive breast carcinomas, which were mostly invasive ductal carcinomas (95.6%), 25 ductal in situ carcinomas and 2 soft-tissue sarcomas. Overall, 90.5% of invasive breast carcinomas were hormone receptor (HR)-positive, 39.5% were human epidermal growth factor receptor 2 (HER2)-positive, and 32.8% showed HR and HER2 co-expression. In addition, 55.4% of patients opted for contralateral prophylactic mastectomy after a first BC diagnosis. There were no significant differences in the risk of developing contralateral BC or in the immunohistochemical profile between p.R337H and non-p.R337H groups. Conclusions: The expressed phenotype of p.R337H is similar to that of other TP53 pathogenic/likely pathogenic variants, except for an average older age at the onset of disease; however, this is still younger than the general population. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Sandoval, Polidorio, Leite, Cartaxo, Pisani, Quirino, Cezana, Pereira, Pereira, Rossi and Achatz.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu